文献速递临床试验与 GCP流行病学与生物统计

口服阿法骨化醇对无继发性甲状旁腺功能亢进的维持性血液透析患者临床结局的影响:J-DAVID随机临床试验

Effect of Oral Alfacalcidol on Clinical Outcomes in Patients Without Secondary Hyperparathyroidism Receiving Maintenance Hemodialysis: The J-DAVID Randomized Clinical Trial.
PubMed 文献 · JAMA · 2018-01-01

J-DAVID随机对照试验纳入976例血清完整甲状旁腺激素≤180 pg/mL的维持性血液透析患者,比较口服阿法骨化醇0.5 μg/日与不用维生素D受体激活剂。结论不支持对此类患者使用维生素D受体激活剂。

要点

  • 在无继发性甲状旁腺功能亢进的维持性血透患者中,口服阿法骨化醇未降低心血管事件风险。

核心结论

  • 在无继发性甲状旁腺功能亢进的维持性血液透析患者中,口服阿法骨化醇与常规治疗相比未降低特定心血管事件复合终点的风险。
  • 研究结果不支持对此类患者使用维生素D受体激活剂。

研究设计与样本

  • 随机、开放标签、盲法终点、多中心研究,在日本207个透析中心进行。
  • 共纳入976例维持性血液透析且血清完整甲状旁腺激素≤180 pg/mL的患者,随机分为阿法骨化醇组(n=495)和对照组(n=481)。
  • 964例纳入意向性治疗分析(中位年龄65岁,女性386例[40.0%]),944例(97.9%)完成试验,中位随访4.0年。

主要发现

  • 阿法骨化醇组严重心血管不良事件199例(40.8%)、感染相关不良事件64例(13.1%)、恶性肿瘤相关严重不良事件22例(4.5%);对照组分别为191例(40.1%)、63例(13.2%)、21例(4.4%)。

临床怎么用

  • 对于血清完整甲状旁腺激素≤180 pg/mL的维持性血液透析患者,不应仅为降低心血管风险而常规使用口服阿法骨化醇。

局限性

  • 研究为开放标签设计,虽采用盲法终点评估,但仍可能存在偏倚。
  • 结果仅适用于血清完整甲状旁腺激素≤180 pg/mL的维持性血液透析患者,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients with chronic kidney disease have impaired vitamin D activation and elevated cardiovascular risk. Observational studies in patients treated with hemodialysis showed that the use of active vitamin D sterols was associated with lower risk of all-cause mortality, regardless of parathyroid hormone levels. OBJECTIVE: To determine whether vitamin D receptor activators reduce cardiovascular events and mortality in patients without secondary hyperparathyroidism undergoing hemodialysis. DESIGN, SETTING, AND PARTICIPANTS: Randomized, open-label, blinded end point multicenter study of 1289 patients in 207 dialysis centers in Japan. The study included 976 patients receiving maintenance hemodialysis with serum intact parathyroid hormone levels less than or equal to 180 pg/mL. The first and last participants were enrolled on August 18, 2008, and January 26, 2011, respectively. The final date of follow-up was April 4, 2015. INTERVENTIONS: Treatment with 0.5 μg of oral alfacalcidol per day (intervention group; n = 495) vs treatment without vitamin D receptor activators (control group; n = 481). MAIN OUTCOMES AND MEASURES: The primary outcome was a composite measure of fatal and nonfatal cardiovascular events, including myocardial infarctions, hospitalizations for congestive heart failure, stroke, aortic dissection/rupture, amputation of lower limb due to ischemia, and cardiac sudden death; coronary revascularization; and leg artery revascularization during 48 months of follow-up. The secondary outcome was all-cause death. RESULTS: Among 976 patients who were randomized from 108 dialysis centers, 964 patients were included in the intention-to-treat analysis (median age, 65 years; 386 women [40.0%]), and 944 (97.9%) completed the trial. During follow-up (median, 4.0 years), the primary composite outcome of cardiovascular events occurred in 103 of 488 patients (21.1%) in the intervention group and 85 of 476 patients (17.9%) in the control group (absolute difference, 3.25% [95% CI, -1.75% to 8.24%]; hazard ratio, 1.25 [95% CI, 0.94-1.67]; P = .13). There was no significant difference in the secondary outcome of all-cause mortality between the groups (18.2% vs 16.8%, respectively; hazard ratio, 1.12 [95% CI, 0.83-1.52]; P = .46). Of the 488 participants in the intervention group, 199 (40.8%) experienced serious adverse events that were classified as cardiovascular, 64 (13.1%) experienced adverse events classified as infection, and 22 (4.5%) experienced malignancy-related serious adverse events. Of 476 participants in the control group, 191 (40.1%) experienced cardiovascular-related serious adverse events, 63 (13.2%) experienced infection-related serious adverse events, and 21 (4.4%) experienced malignancy-related adverse events. CONCLUSIONS AND RELEVANCE: Among patients without secondary hyperparathyroidism undergoing maintenance hemodialysis, oral alfacalcidol compared with usual care did not reduce the risk of a composite measure of select cardiovascular events. These findings do not support the use of vitamin D receptor activators for patients such as these. TRIAL REGISTRATION: UMIN-CTR Identifier: UMIN000001194.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Shoji T, Inaba M, Fukagawa M, et al. Effect of Oral Alfacalcidol on Clinical Outcomes in Patients Without Secondary Hyperparathyroidism Receiving Maintenance Hemodialysis: The J-DAVID Randomized Clinical Trial. JAMA. 2018. PMID: 30535217. doi:10.1001/jama.2018.17749

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。